Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human tyrosinase DNA vaccine
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The human tyrosinase DNA vaccine is an experimental immunotherapy developed by Memorial Sloan Kettering Cancer Center for the treatment of melanoma. It consists of a pING plasmid vector encoding the human tyrosinase cDNA under the control of a cytomegalovirus (CMV) promoter. Tyrosinase is a key enzyme in melanin biosynthesis and serves as a melanosomal differentiation antigen that is highly expressed in most melanoma cells. By delivering the DNA sequence directly into host cells (typically via intramuscular injection), the vaccine aims to induce a specific T-cell mediated immune response against melanoma cells expressing the tyrosinase antigen. In clinical settings, this vaccine has been evaluated in Phase I trials, often administered in a sequential prime-boost strategy alongside a xenogeneic mouse tyrosinase DNA vaccine to enhance immunogenicity and overcome self-tolerance to the human protein.
- Other names
- human tyrosinase plasmid DNA vaccinehTYR DNA vaccinehuman tyrosinase DNA vaccine-Memorial Sloan Kettering Cancer Center-melanoma
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on human tyrosinase DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human tyrosinase DNA vaccine.